HBS Capital ApS
- Adresse
- Energivej 15
5260 Odense S
HBS Capital ApS is a holding company established and ultimately owned by the Bøgh-Sørensen family. The Group’s primary business activity is being an ambitious operator in the European market for pharmaceuticalsthrough the investment in Orifarm Group A/S, which is the largest supplier of parallel imported pharmaceuticals in Europe, and a producer and seller of well-known brands as well as generic pharmaceuticals. Secondly the HBS Capital Group invests across a broad range of asset classes including Private Equity, Real Estate,Investment cars and other financial assets both public and private,…
Regnskabsår 01.01.2025 – 31.12.2025 · beløb i EUR. Viser moderselskab · vis koncern
Regnskab (t.eur)
| 2025 | 2024 | |
|---|---|---|
| Resultatopgørelse | ||
| Bruttofortjeneste | -6 | -4 |
| Finansielle indtægter | 4 | 3 |
| Resultat før skat | 9.227 | 580 |
| Skat af årets resultat | -1 | -1 |
| Årets resultat | 9.228 | 581 |
| Balance | ||
| Anlægsaktiver | 131.842 | – |
| Omsætningsaktiver | 3 | – |
| Likvide beholdninger | 2 | – |
| Aktiver i alt | 131.845 | – |
| Selskabskapital | 637 | – |
| Overført resultat | 74.483 | – |
| Egenkapital | 131.799 | – |
| Kortfristet gæld | 46 | – |
| Foreslået udbytte | 4.418 | – |
| Nøgletal | ||
| Egenkapitalforrentning | 7,0 % | – |
| Soliditetsgrad | 100,0 % | – |
| Likviditetsgrad | 7 % | – |
| Antal ansatte | 0 | – |
Ledelse
- Hans Bøgh-SørensenDirektion
Ifølge underskrifterne i årsrapporterne. Personer identificeres ud fra navn.
Revision
- Deloitte Statsautoriseret RevisionspartnerselskabRevisionspåtegning · 2024–2025
Seneste erklæring: Revisionspåtegning